Deepak Lab

@WUGastro PI @P_DeepakIBDMD with focus on refractory IBD & Cardiometabolic disease across translational and interventional studies, novel imaging & RWE studies

[Deepak Lab @P_DeepakIBDLab]

New Pub Alert‼️ @P_DeepakIBDLab @P_DeepakIBDMD
@AmerGastroAssn @AGA_GHAdvances
Novel 💩 eukaryotic RNA-based (seRNA) reliably discriminates 🔥disease from remission & stratifies mild from moderate CD activity.
Collaboration @GeneoscopyCo @EricaBarnell
https://t.co/J4QAe8ERdR

[AASLD @AASLDtweets]

🔥 HOT TOPIC

📗 @HEP_Journal

Potentially practice-changing for patients with #MASLD and #type2diabetes, this study found that a #GLP-1 receptor agonist–SGLT-2 inhibitor combination was associated with a lower risk of major adverse liver and cardiovascular outcomes compared with either therapy alone.

The study also highlights an innovative use of emulation trial methodology to evaluate potential clinical efficacy in the absence of prospective randomized trials.

Read the article here ➡️ https://t.co/Or3ZBV6ihR

[Jalpa Devi @jalpa_devi]

1/💫Honored to collaborate with the incredible 👨‍⚕️👩‍⚕️ from the #REBOOTIBD consortium & #NorthAmericanCenters
@P_DeepakIBDMD @P_DeepakIBDLab
🤩This work highlights the growing role of real-world evidence and multidisciplinary care for #pCD
#WorldIBDDay 👇
https://t.co/cm35HDomvf

[Edward Loftus @EdwardLoftus2]

Happy World IBD Day to those who celebrate (and everyone should celebrate) #WorldIBDDay @MayoClinicGIHep

[Zeinab Bakhshi MD @z_bakhshiii]

📈🔥 Proctectomy in pfCD is STILL happening despite advanced therapies!
🧠 TriNetX cohort (2005–2025): ➡️ Proctectomy ↑ from 0.30% → 1.19% ⬆️
💊 Trends by therapy:
🔹 Anti-TNF ⬆️
🔹 Anti-integrin ⬆️
🔹 Ustekinumab ⬆️
🔹 Upadacitinib ⬆️ (highest 📊)
🔹 Anti–IL-23 ➡️ (stable)
⚠️ Bottom line: Even in the biologic/JAK era… a subset of pfCD remains refractory → surgery 🏥✂️
#IBD #Crohns present by Thabet Qapaja from
@P_DeepakIBDMD @P_DeepakIBDLab
@LuluNut23
@DDWMeeting #DDW2026

[Zeinab Bakhshi MD @z_bakhshiii]

🧠 Multi-center cohort (≥1 yr FU) using MRI:
✔️ Healed → 93% sustained remission, 7% recurrence
❌ Not healed → 78% remission, 22% recurrence
@AmerGastroAssn @LuluNut23

[Zeinab Bakhshi MD @z_bakhshiii]

TOPClass-RH shows international, real-world, multicultural validation for radiographic fistula healing in pFCD 🌍
✔️ Highly reliable (>95% agreement)
✔️ Predictive → ~93% sustained remission
👉 Strong candidate for a treat-to-target endpoint
Presented by @SamiSamaanMD @P_DeepakIBDMD @P_DeepakIBDLab @DDWMeeting #DDW2026

[JAMA Internal Medicine @JAMAInternalMed]

Continuing #GLP1 or GIP agonists before upper endoscopy increased the risk of clinically significant residual gastric volume, with no additional aspiration events.

https://t.co/82QlkwzNIz

[Parakkal Deepak MD, MS, FACG @P_DeepakIBDMD]

Nice work @SamiSamaanMD @P_DeepakIBDLab MRI-based standard may predict outcomes in perianal Crohn's https://t.co/tpzzBjz1Ex

[Parakkal Deepak MD, MS, FACG @P_DeepakIBDMD]

@Siyan_Cao Very well deserved! The first of many to come! @WashUMedGastro @WashUMedIBD @CiorbaGI @NODGastro

[Deepak Lab @P_DeepakIBDLab]

@SamiSamaanMD @P_DeepakIBDMD We make a great team!

[Sami Samaan @SamiSamaanMD]

@P_DeepakIBDMD @P_DeepakIBDLab Best mentor you could ask for! Thank you for all the support, great work is being done in @P_DeepakIBDLab

[Parakkal Deepak MD, MS, FACG @P_DeepakIBDMD]

Future 🌟 guy in GI, who is going to go very far in life! Glad to have you as a research fellow in my lab @P_DeepakIBDLab and lots of great work together coming through!

[Deepak Lab @P_DeepakIBDLab]

RT @P_DeepakIBDMD: Wishing everyone Happy Holidays from my lab group @P_DeepakIBDLab . Image courtesy my research fellow @SamiSamaanMD who…

[Deepak Lab @P_DeepakIBDLab]

@GI_Pearls Have to agree! I suspect this may have more to do with biomagnification of environmental toxins (using it broadly) than just the red meat itself. Also the alcohol going in with the meat plus the lack of exercise etc.

[Parakkal Deepak MD, MS, FACG @P_DeepakIBDMD]

👉Team science🧪🧬↔️💻↔️scanner @WUGastro @MIRimaging @P_DeepakIBDLab @DavidBallardMD
👉Basic labs: https://t.co/EbqyD0sTyC, https://t.co/w3Hlf0HVlR
👉 Datasets: 🧪💻https://t.co/GfkcAU5rEe, https://t.co/9qjs6aE1Tn & @WashUi2 @MDCloneHQ iIBD Multicenter: @SPARCIBD, REBOOT-IBD

[Parakkal Deepak MD, MS, FACG @P_DeepakIBDMD]

✅#IBD interventional endoscopy @BalissMichelle
✅Rotate @WashUColorectal @wusm_pathology @MIRimaging
✅Education: Annual #IBD CME & Research symposium/quarterly Gut Club, monthly research and path/rad IBD case conference

[Parakkal Deepak MD, MS, FACG @P_DeepakIBDMD]

Why @WashUMedIBD?
✅100% Graduates in academia @jalpa_devi
✅Opportunities for prolific research output & extensive clinical exposure serving 4-5 hour radius @WUGastro
✅ Team 11 GIs, 2 ANPs, GI psych, dietician @kristin_gi_rd
✅ @BowelUltrasound #MateGergely

[Parakkal Deepak MD, MS, FACG @P_DeepakIBDMD]

Eligibility:
✅Completed or will complete GI fellowship by June 2026 (US, Canadian, international)
✅Eligible for Missouri medical license
✅Interview Zoom or in person
✅J-1 visas welcome for Foreign Medical Graduates @jalpa_devi
🌐Apply now + shape the future of IBD care!

[Parakkal Deepak MD, MS, FACG @P_DeepakIBDMD]

🎓 NOW ACCEPTING APPLICATIONS
🔬 Advanced IBD Fellowship July 1, 2026 – June 30, 2027 @WashUMedGastro @WashUMedIBD
Specialized, hands-on experience in Inflammatory Bowel Disease care, research, innovation.
📷📩 [email protected]
🔗https://t.co/4Rh6WdEm56
📷 @WashUMedIBD

[Parakkal Deepak MD, MS, FACG @P_DeepakIBDMD]

Such an 🤩 experience & personally learned a lot from the patient advocates who were so generous with their time/experience that will shape not only next steps we are doing from this event but also in designing pt centric studies in our research projects! @P_DeepakIBDLab